Explore our publications, posters, and presentations

Journal Publications

  1. Orlando E, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, Levine JE, Qayed M, Grupp SA, Boyer M, De Moerloose B, Nemecek ER, Bittencourt H, Hiramatsu H, Büchner J, Davies SM, Verneris M, Nguyen K, Brogdon JL, Bitter H, Morrissey M, Pierog P, Pantano S, Engelman JA, and Winckler W. Genetic alterations in CD19 lead to CD19 negative relapse to CAR19 therapy in children and young adults with relapsed/refractory acute lymphoblastic leukemia. Nature Medicine 2018; 24(10):1504–1506.   doi:10.1038/s41591-018-0146-z
  2. Johnson DB, Bordeaux J, Kim J, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, and Dakappagari N.  Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of anti-PD-1 Therapies in Metastatic Melanoma. Clinical Cancer Research, 2018 Nov 1; 24(21):5250-5260.  doi:10.1158/1078-0432
  3. Everett AS, Pavlidakey PG, Contreras CM, De Los Santos JF, Kim J, McKee SB, Kaufman HL, and Conry RM. Chronic Granulomatous Dermatitis Induced by Talimogene Laherparepvec Therapy of Melanoma Metastases. J Cutan Pathol. 2017 Sep 22. doi:10.1111/cup.13048
  4. Rost S, Giltnane J, Bordeaux JM, Hitzman C, Koeppen H, and Liu SD. Multiplexed ion-beam imaging (MIBI) analysis for quantitation of protein expression on cancer tissue sections. Lab Invest. 2017 Aug;97(8):992-1003. doi:10.1038/labinvest.2017.50
  5. Blackmon JT, Stratton MS, Kwak Y, Pavlidakev PG, Slominski AT, McKee SB, Viator TM, Kim J, Huang CC, and Conry RM. Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec. JAAD Case Reports, 2017 Jun 16;3(4):280-283. doi:10.1016/j.jdcr.2017.02.011
  6. Siska PJ, Johnpulle RAN, Zhou A, Bourdeaux J, Kim J, Dabbas B, Dakappagari N, Rathmell JC, Rathmell WK, Morgans AK, Balko JM, and Johnson DB. Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. Oncoimmunology. 2017 Mar 20;6(4):e1305535. doi:10.1080/2162402X.2017.1305535
  7. Beckermann KE, Jolly PC, Kim J, Bordeaux J, Puzanov I, Rathmell WK, and Johnson DB. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic Renal Medullary Carcinoma. J Immunother Cancer. 2017 Jan; 5: 1. doi:10.1186/s40425-016-0206-1
  8. Dakappagari N, Gong H, Pollner R, Siva A, Tangri S, and Lameh J. Application of Biomarkers in Oncology Clinical Trials. Clinical Investigation, 2015; 5(1):61-74. doi:10.4155/CLI.14.106
  9. O'Shannessy DJ, Somers EB, Chandrasekaran LK, Nicolaides NC, Bordeaux J, and Gustavson MD. Influence of tumor microenvironment on prognosis in colorectal cancer: Tissue architecture-dependent signature of endosialin (TEM-1) and associated proteins. Oncotarget. 2014 Jun 30;5(12):3983-95.doi:10.18632/oncotarget.2108
  10. Vassilakopoulou M, Togun T, Dafni U, Cheng H, Bordeaux J, Neumeister VM, Bobos M, Pentheroudakis G, Skarlos DV, Pectasides D, Kotoula V, Fountzilas G, Rimm DL, and Psyrri A. In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients. PLoS One. 2014 Jun 26;9(6):e99131. doi: 10.1371/journal.pone.0099131
  11. Bai Y, Cheng H, Bordeaux J, Neumeister V, Kumar S, Rimm DL, and Stern DF. Comparison of HER2 and Phospho-HER2 Expression between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment Method. PLoS One. 2013 Dec 8(11): e79901. doi:10.1371/journal.pone.0079901